Table 1 Information of the patients in FDUHS cohort
Patients | Gender | Age | Treatment | Response | Subtype |
|---|---|---|---|---|---|
P1 | Male | 24 | Vedolizumab | NR | IIA |
P2 | Male | 59 | Vedolizumab | NR | IHL |
P3 | Female | 49 | Vedolizumab | NR | WIA |
P4 | Male | 31 | Vedolizumab | R | IHL |
P5 | Female | 39 | Vedolizumab | NR | WIA |
P6 | Female | 42 | Infliximab | NR | WIA |
P7 | Female | 54 | Infliximab | R | IHL |
P8 | Female | 34 | Infliximab | R | IHL |
P9 | Male | 40 | Vedolizumab | NR | WIA |
P10 | Male | 43 | Vedolizumab | NR | WIA |
P11 | Male | 63 | Vedolizumab | R | IHL |
P12 | Male | 62 | Vedolizumab | NR | IHL |